Add Yahoo as a preferred source to see more of our stories on Google. Invivyd had also attempted to attain regulatory approval for pemivibart.Credit: Design_Cells via Shutterstock. At IDWeek 2025, ...

Compared with placebo, ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in uninfected individuals following exposure to an infected individual through day 10. The Food and ...

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

MONDAY, June 8, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and ...

A Prescription Drug User Fee Act target date of June 16, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...

Xocova is a 5-day oral regimen with 3 tablets taken as a single dose on day 1 then 1 tablet taken on days 2 through 5. Compared with placebo, ensitrelvir significantly reduced the risk of symptomatic ...